Merck combination treatment for lung cancer fails late-stage study

[March 21, 2024]  (Reuters) - Merck said on Thursday a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.

The treatment, which combines Keytruda and AstraZeneca-partnered Lynparza, failed to extend survival in patients and survival without the disease worsening in certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).

The company says a full evaluation of the studies was underway.

(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.